Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer
- PMID: 28841388
- PMCID: PMC5648173
- DOI: 10.1200/JCO.2017.72.6109
Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer
Abstract
Purpose To assess the relative risk of Alzheimer's disease (AD) among patients with prostate cancer who received androgen deprivation therapy (ADT), after adjustment for other cancer therapies. Methods Data from demographics, survival, diagnoses codes, procedure codes, and other information about beneficiaries age 67 years or older in the Medicare claims database was assessed to determine the unadjusted and adjusted risks of AD and of dementia from ADT. The prespecified survival analysis method was competing risk regression. Results Of the 1.2 million fee-for-service Medicare beneficiaries who developed prostate cancer in 2001 to 2014, 35% received ADT. Of these, 109,815 (8.9%) and 223,765 (18.8%) developed AD and dementia, respectively, and 26% to 33% died without either outcome. Unadjusted rates of AD and all-cause mortality per 1,000 patient-years were higher among ADT recipients; the unadjusted rates of AD were 17.0 and 15.5 per 1,000 person-years in recipients and nonrecipients, respectively, and the unadjusted rates of all-cause mortality were 73.0 and 51.6 per 1,000 person-years, respectively. The unadjusted rates for dementia in ADT recipients versus nonrecipients were 38.5 and 32.9, respectively, and the unadjusted rates of mortality were 60.2 versus 40.4, respectively. However, after analysis was adjusted for other cancer therapies and other covariates, patients with ADT treatment had no increased risk of AD (subdistribution hazard ratio [SHR], 0.98; 95% CI, 0.97 to 0.99) and had only a miniscule (1%) risk of dementia (SHR, 1.01; 95% CI, 1.01 to 1.02); patients treated with ADT were more likely to die before progression to AD (SHR, 1.24; 95% CI, 1.23 to 1.24) or dementia (SHR, 1.26; 95% CI, 1.25 to 1.26). The risks of AD and dementia were not associated with duration of ADT (ie, no dose effect). Other secondary analyses confirmed these results. Conclusion These data suggest that ADT treatment has no hazard for AD and no meaningful hazard for dementia among men age 67 years or older who are enrolled in Medicare.
Figures
Comment in
-
Androgen Deprivation Therapy and Dementia: New Opportunities and Challenges in the Big-Data Era.J Clin Oncol. 2017 Oct 20;35(30):3380-3381. doi: 10.1200/JCO.2017.74.8806. Epub 2017 Aug 25. J Clin Oncol. 2017. PMID: 28841386 No abstract available.
Similar articles
-
Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.JAMA Netw Open. 2019 Jul 3;2(7):e196562. doi: 10.1001/jamanetworkopen.2019.6562. JAMA Netw Open. 2019. PMID: 31268539 Free PMC article.
-
Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.Pharmacotherapy. 2018 Oct;38(10):999-1009. doi: 10.1002/phar.2168. Epub 2018 Sep 4. Pharmacotherapy. 2018. PMID: 30080934
-
Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.Prostate Cancer Prostatic Dis. 2020 Sep;23(3):410-418. doi: 10.1038/s41391-019-0189-3. Epub 2019 Nov 29. Prostate Cancer Prostatic Dis. 2020. PMID: 31784699
-
Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2017 Sep;20(3):259-264. doi: 10.1038/pcan.2017.10. Epub 2017 Mar 28. Prostate Cancer Prostatic Dis. 2017. PMID: 28349979 Review.
-
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.Eur Urol Focus. 2020 Nov 15;6(6):1170-1179. doi: 10.1016/j.euf.2020.05.014. Epub 2020 Jul 18. Eur Urol Focus. 2020. PMID: 32690473 Review.
Cited by
-
A Large Retrospective Cohort Study on the Risk of Alzheimer's Disease and Related Dementias in Association with Vascular Diseases and Cancer Therapy in Men with Prostate Cancer.J Prev Alzheimers Dis. 2023;10(2):193-206. doi: 10.14283/jpad.2023.8. J Prev Alzheimers Dis. 2023. PMID: 36946446 Free PMC article.
-
A Systematic Review on the Potential Acceleration of Neurocognitive Aging in Older Cancer Survivors.Cancers (Basel). 2023 Feb 14;15(4):1215. doi: 10.3390/cancers15041215. Cancers (Basel). 2023. PMID: 36831557 Free PMC article. Review.
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
-
Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy.Prostate. 2022 Oct;82(14):1389-1399. doi: 10.1002/pros.24411. Epub 2022 Jul 12. Prostate. 2022. PMID: 35821621 Free PMC article.
-
The Insignificant Correlation between Androgen Deprivation Therapy and Incidence of Dementia Using an Extension Survival Cox Hazard Model and Propensity-Score Matching Analysis in a Retrospective, Population-Based Prostate Cancer Registry.Cancers (Basel). 2022 May 30;14(11):2705. doi: 10.3390/cancers14112705. Cancers (Basel). 2022. PMID: 35681684 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016 - PubMed
-
- Nead KT, Gaskin G, Chester C, et al. : Association between androgen deprivation therapy and risk of dementia. JAMA Oncol 3:49-55, 2017 - PubMed
-
- Hogervorst E, Bandelow S, Combrinck M, et al. : Low free testosterone is an independent risk factor for Alzheimer’s disease. Exp Gerontol 39:1633-1639, 2004 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical